141 related articles for article (PubMed ID: 33035223)
1. Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor.
Chang TC; Matossian MD; Elliott S; Burks HE; Sabol RA; Ucar DA; Wathieu H; Zabaleta J; Del Valle L; Gill S; Martin E; Riker AI; Miele L; Bunnell BA; Burow ME; Collins-Burow BM
PLoS One; 2020; 15(10):e0226464. PubMed ID: 33035223
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma.
McGuire JJ; Nerlakanti N; Lo CH; Tauro M; Utset-Ward TJ; Reed DR; Lynch CC
Int J Cancer; 2020 Nov; 147(10):2811-2823. PubMed ID: 32599665
[TBL] [Abstract][Full Text] [Related]
3. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
5. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers.
Cooper SJ; von Roemeling CA; Kang KH; Marlow LA; Grebe SK; Menefee ME; Tun HW; Colon-Otero G; Perez EA; Copland JA
Mol Cancer Ther; 2012 Oct; 11(10):2105-15. PubMed ID: 22826467
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines.
Zopf S; Ocker M; Neureiter D; Alinger B; Gahr S; Neurath MF; Di Fazio P
BMC Cancer; 2012 Sep; 12():386. PubMed ID: 22943463
[TBL] [Abstract][Full Text] [Related]
7. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
8. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation.
Harttrampf AC; da Costa MEM; Renoult A; Daudigeos-Dubus E; Geoerger B
BMC Cancer; 2021 Jul; 21(1):833. PubMed ID: 34281526
[TBL] [Abstract][Full Text] [Related]
10. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
12. Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Chen JH; Huang WC; Bamodu OA; Chang PM; Chao TY; Huang TH
BMC Cancer; 2019 Jun; 19(1):634. PubMed ID: 31248373
[TBL] [Abstract][Full Text] [Related]
13. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
14. Panobinostat (LBH589) inhibits Wnt/β-catenin signaling pathway via upregulating APCL expression in breast cancer.
Qin G; Li Y; Xu X; Wang X; Zhang K; Tang Y; Qiu H; Shi D; Zhang C; Long Q; Lee K; Zhai Q; Wang S; Chen M; Deng W
Cell Signal; 2019 Jul; 59():62-75. PubMed ID: 30880222
[TBL] [Abstract][Full Text] [Related]
15. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis.
Robertson FM; Chu K; Boley KM; Ye Z; Liu H; Wright MC; Moraes R; Zhang X; Green TL; Barsky SH; Heise C; Cristofanilli M
J Exp Ther Oncol; 2013; 10(3):219-33. PubMed ID: 24416998
[TBL] [Abstract][Full Text] [Related]
16. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis.
Wei C; Yang C; Wang S; Shi D; Zhang C; Lin X; Liu Q; Dou R; Xiong B
Mol Cancer; 2019 Mar; 18(1):64. PubMed ID: 30927925
[TBL] [Abstract][Full Text] [Related]
17. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway.
Qin G; Xu F; Qin T; Zheng Q; Shi D; Xia W; Tian Y; Tang Y; Wang J; Xiao X; Deng W; Wang S
Oncotarget; 2015 Dec; 6(39):41794-808. PubMed ID: 26540629
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Shah P; Gau Y; Sabnis G
Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
20. The histone deacetylase inhibitor LBH589 inhibits undifferentiated pleomorphic sarcoma growth via downregulation of FOS-like antigen 1.
Saitoh Y; Bureta C; Sasaki H; Nagano S; Maeda S; Furukawa T; Taniguchi N; Setoguchi T
Mol Carcinog; 2019 Feb; 58(2):234-246. PubMed ID: 30303565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
